预约演示
更新于：2026-10-23
Agomelatine
阿戈美拉汀
更新于：2026-10-23
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 欧盟 (2009-02-19), |
最高研发阶段(中国)批准上市 |
特殊审评儿科研究计划 (欧盟) |
登录后查看时间轴
结构/序列
分子式C15H17NO2 |
InChIKeyYJYPHIXNFHFHND-UHFFFAOYSA-N |
CAS号138112-76-2 |
关联
164
项与 阿戈美拉汀 相关的临床试验CTIS2025-522967-13-00
A multicenter randomized, controlled, single-blind, adaptive phase IV clinical trial to evaluate the efficiency and effectiveness of a pre-emptive pharmacogenetic strategy for antidepressant selection in patients with depressive disorder: The PREDICT adaptive clinical trial.
IRCT20090117001556N164
The effect of Agomelatine as an adjuvant therapy on the improvement of negative symptoms in patients with chronic schizophrenia: A randomized, double-blind, placebo-controlled trial
ACTRN12625000575437
Part A: Phase 1, Single- Ascending Dose Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of Agomelatine in Healthy Participants.
100 项与 阿戈美拉汀 相关的临床结果
登录后查看更多信息
100 项与 阿戈美拉汀 相关的转化医学
登录后查看更多信息
100 项与 阿戈美拉汀 相关的专利（医药）
登录后查看更多信息
1,150
项与 阿戈美拉汀 相关的文献（医药）2026-12-01MOLECULAR BIOLOGY REPORTS
Agomelatine versus gefitinib against HepG2 cells: Modulating PI3K/AKT and MAPK/RAF1/c-FOS pathways
Article
作者: Al-Saraireh, Yousef ; ELdaly, Mai M ; Abd El Kareem, Heba M ; Saadawy, Sara F ; Hassan, Heba A
BACKGROUND:
Hepatocellular carcinoma (HCC) is the predominant form of cancer globally, characterized by a dismal prognosis and few treatment options. Agomelatine (AGO) acts as a melatonin receptor agonist and a 5-HT2C receptor antagonist, suggesting its potential anticancer efficacy across diverse cancer types.
AIM:
This study aims to assess the effects of AGO and gefitinib (GEF) on apoptosis, cell cycle, and caspase expression, and to examine their implications for the PI3K/AKT and MAPK/ERK pathways.
METHODS:
The concentrations of AGO and GEF were altered in the cells. MTT tests (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) were used. A flow cytometry experiment was conducted after a single dose of AGO and GEF. The RT-qPCR test was used to assess the expression levels of caspases 8 and 9, as well as the PI3K/AKT and MAPK/RAF/c-FOS genes.
RESULTS:
AGO and GEF increased caspase expression, reduced cell viability, and induced apoptosis while inhibiting the expression of PI3K/AKT and MAPK/ERK genes.
CONCLUSION:
Our results demonstrated that both AGO and GEF impeded HCC progression by enhancing apoptosis and caspase expression while modulating the PI3K/AKT and MAPK/RAF/c-FOS signaling pathways, suggesting that AGO and GEF may serve as effective therapeutic options for HCC, with gefitinib exhibiting greater potential as an anticancer agent.
2026-11-01CNS DRUGS
Next-Generation Pharmacotherapies for Unipolar Mood Disorders: A Leading Article on Phase II/III Drug Development Across Diverse Mechanisms
Review
作者: Rhee, Taeho Greg ; King, Alana ; Hardy, Morgan ; Wilkinson, Samuel T
Despite the wide prevalence of mood disorders globally, there is a substantial unmet need for effective, mechanistically distinct treatments. Given that approximately 30% of individuals do not display adequate response to standard antidepressant therapies, the past 15 years have seen a shift away from traditional monoaminergic approaches toward glutamatergic and other novel mechanisms. Following the US Food and Drug Administration (FDA) approval of esketamine and brexanolone in 2019, industry investment in therapeutics with novel mechanisms for mood and anxiety disorders has expanded, catalyzing a new wave of innovative interventions. This review summarizes progress for unipolar mood disorders in four categories-glutamatergic/GABA modulators, ion channel modulators, psychedelics, and other potential therapeutic mechanisms-focusing on Phase II/III industry-sponsored US clinical trials active within the past 3 years. The drug names discussed are ALTO-100, ALTO-203, ALTO-207, ALTO-300, BHV-7000, BI-1569912, BPL-003, COMP360, DT120, ELE-101, GATE-251, GH001, GM-1020, GM-2505, HLP003, MK-1942, NBI-1065845, NBI-1070770, NV-5138, PIPE-307, SEP-363856, SPT-300, VLS-01, and XEN1101. The US Clinical Trials registry (clinicaltrials.gov), MEDLINE, conference proceedings, and company communications such as press releases were consulted to obtain up-to-date trial information and reported outcomes. Overall, the therapeutic landscape shows an expanding range of clinical compounds under active development; nonetheless, persistent challenges remain, including approaches to therapeutics where functional unblinding may occur, the ways in which to consider a novel conceptualization of occupancy-driven versus event-driven pharmacology, and the role of supporting psychotherapy.
2026-11-01JOURNAL OF AFFECTIVE DISORDERS
Investigating the effects of antidepressants on measures of insulin resistance in major depressive disorder: A systematic review
Review
作者: Zheng, Yang Jing ; McIntyre, Roger S ; Guillen-Burgos, Hernan F ; Teopiz, Kayla ; Le, Gia Han ; Dri, Christine E ; Wong, Sabrina
BACKGROUND:
Persons with depression are disproportionately at risk for developing insulin resistance. Replicated evidence indicates that insulin resistance blunts acute antidepressant response; however, some antidepressants exacerbate insulin resistance risk. Herein, we aim to comprehensively evaluate previous literature reporting on the effects of antidepressants on measures of insulin resistance with the view to disaggregate class- and drug-specific effects.
METHODS:
A systematic search on PubMed, Ovid and Scopus (inception-July 2025) was conducted, with a manual search of Google Scholar and reference lists. Two reviewers (S.W. and G.H.L.) independently screened studies. Clinical trials investigating FDA-approved antidepressants on a validated measure of insulin resistance were included. Studies were assessed using the National Institute of Health quality assessment tools.
RESULTS:
Select tricyclic antidepressants (i.e., nortriptyline, amitriptyline, imipramine) were associated with acute and long-term disruptions in insulin sensitivity. SSRIs were not associated with acute alterations in insulin sensitivity. Preliminary evidence suggests agomelatine and bupropion are metabolically neutral and may improve insulin resistance in persons with diabetes mellitus. SNRIs do not adversely affect glucose-insulin signaling in the long-term. There was a paucity of studies reporting the effects of other antidepressant classes and agents.
CONCLUSION:
The effect of antidepressants on mechanisms mediating insulin sensitivity is mixed, with a relatively limited body of evidence currently available. While select SSRIs and tricyclic antidepressants may adversely affect glucose-insulin homeostasis, conclusions remain preliminary. The development of novel antidepressants may provide an opportunity to optimize psychiatric and metabolic outcomes. Identifying mechanisms contributing to insulin resistance could inform future discovery and development of antidepressants.
100 项与 阿戈美拉汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 广泛性焦虑障碍 | 澳大利亚 | 2010-08-09 | |
| 重度抑郁症 | 欧盟 | 2009-02-19 | |
| 重度抑郁症 | 欧盟 | 2009-02-19 | |
| 重度抑郁症 | 冰岛 | 2009-02-19 | |
| 重度抑郁症 | 冰岛 | 2009-02-19 | |
| 重度抑郁症 | 列支敦士登 | 2009-02-19 | |
| 重度抑郁症 | 列支敦士登 | 2009-02-19 | |
| 重度抑郁症 | 挪威 | 2009-02-19 | |
| 重度抑郁症 | 挪威 | 2009-02-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 躁郁症1型 | 临床3期 | 奥地利 | 2006-05-01 | |
| 躁郁症1型 | 临床3期 | 奥地利 | 2006-05-01 | |
| 强迫症 | 临床2期 | 以色列 | 2010-05-01 | |
| 终末期肾脏病 | 临床1期 | 美国 | 2011-03-01 | |
| 自闭症 | 临床阶段不明 | 美国 | 2012-08-17 | |
| 疼痛 | 临床阶段不明 | 美国 | 2012-08-17 | |
| 抑郁症 | 临床申请批准 | 中国 | 2024-05-14 | |
| 帕金森病 | 临床前 | 中国 | 2025-11-30 | |
| 脑损伤 | 临床前 | 印度 | 2025-06-10 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 123 | 襯簾鏇獵淵願衊遞壓觸(壓淵壓醖鏇獵蓋餘鏇膚): P-Value = 0.90 | 不佳 | 2025-03-05 | |||
Placebo | |||||||
临床2期 | 87 | 餘蓋夢壓憲製選構願艱(繭襯襯艱觸醖艱製衊廠) = the development of novel precision medicines for neuropsychiatric disorders, today announced a favorable outcome from the planned interim analysis for the Phase 2b trial of ALTO-300 as an adjunctive treatment for patients with major depressive disorder (MDD). 築鏇鬱範膚構鑰糧鬱範 (艱觸遞淵鹹願鬱鏇選網 ) | 积极 | 2025-02-12 | |||
临床2期 | 239 | (biomarker-characterized patients) | 襯顧簾繭衊觸築窪繭壓(艱構顧簾膚願遞願願夢) = 積壓積網範淵醖觸網鬱 醖艱繭構網築憲窪簾築 (糧餘夢齋鏇壓鏇簾艱選 ) 更多 | 积极 | 2023-12-04 | ||
临床3期 | 222 | 積窪觸製網鏇選獵餘鑰(廠糧壓鏇鹹鹹衊選願鏇) = 範選襯窪網襯窪鬱選餘 繭餘簾觸襯衊衊選鹽選 (廠襯鹹觸鹽鏇憲繭顧鹽 ) | 积极 | 2013-06-01 | |||
Placebo | 積窪觸製網鏇選獵餘鑰(廠糧壓鏇鹹鹹衊選願鏇) = 鬱廠衊醖廠淵襯觸鏇窪 繭餘簾觸襯衊衊選鹽選 (廠襯鹹觸鹽鏇憲繭顧鹽 ) | ||||||
临床4期 | 332 | 糧願憲壓製夢範鑰艱膚(獵製願齋鹹憲淵遞鏇築) = 衊醖遞顧鑰鹽顧蓋獵顧 糧積獵繭蓋壓蓋願糧獵 (遞糧範餘齋範餘襯選餘 ) | 积极 | 2007-11-01 | |||
Venlafaxine 75-150 mg/day | 糧願憲壓製夢範鑰艱膚(獵製願齋鹹憲淵遞鏇築) = 觸選構繭餘觸積製遞構 糧積獵繭蓋壓蓋願糧獵 (遞糧範餘齋範餘襯選餘 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用